Related Experiment Video

Updated: Mar 31, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Multidrug Resistance Protein-4 Influences Aspirin Toxicity in Human Cell Line

Isabella Massimi1, Ambra Ciuffetta2, Flavia Temperilli1

  • 1Department of Experimental Medicine, Faculty of Medicine and Surgery, Sapienza University of Rome, 00161 Rome, Italy.

Mediators of Inflammation
|October 23, 2015
PubMed

Insights

Low-dose aspirin exposure increases multidrug resistance protein-4 (MRP4) gene expression in human cells. This can lead to MRP4 overexpression, enhancing cellular detoxification and reducing aspirin

Area of Science:

  • Pharmacology and Toxicology
  • Molecular Biology
  • Cell Biology

Background:

  • Overexpression of efflux transporters, such as multidrug resistance protein-4 (MRP4), is a key mechanism for cellular resistance to drugs and chemotherapy.
  • MRP4 overexpression has been implicated in reduced aspirin efficacy, particularly in post-bypass surgery patients.
  • Aspirin has been shown to enhance platelet MRP4 levels via peroxisome proliferator activated receptor-α (PPARα).

Purpose of the Study:

  • To investigate whether aspirin exposure modifies MRP4 gene expression in human embryonic kidney-293 (HEK-293) cells.
  • To determine the correlation between aspirin-induced MRP4 changes, drug elimination, and cellular toxicity.
  • To assess the impact of MRP4 overexpression on aspirin's cell growth inhibitory effects.

Main Methods:

  • Exposure of HEK-293 cells to varying doses of aspirin.
  • Dose-response analysis of aspirin's effect on cell toxicity.
  • Measurement of MRP4 gene expression following low-dose aspirin treatment.
  • Comparison of cell viability in MRP4-overexpressing cells (via aspirin pretreatment or transfection) versus control cells after high-dose aspirin treatment.

Main Results:

  • Aspirin increased cell toxicity in HEK-293 cells in a dose-dependent manner.
  • Low-dose aspirin exposure significantly enhanced MRP4 gene expression.
  • MRP4 overexpression, either induced by aspirin pretreatment or through transfection, attenuated aspirin's selective cell growth inhibition.

Conclusions:

  • Exposure to low, non-toxic aspirin doses can induce alterations in gene expression, leading to efflux transporter (MRP4) overexpression.
  • MRP4 overexpression enhances the cellular detoxification of aspirin, potentially reducing its therapeutic efficacy.
  • These findings highlight a mechanism by which aspirin itself can modulate its own action through adaptive cellular responses.

More Related Videos

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration10:43

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration

Published on: May 19, 2016

7.1K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
337
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
171
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
170
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62